Chinemerem M. Emeasoba

Articles by Chinemerem M. Emeasoba

72 Clonal Hematopoiesis and Anthracycline Cardiotoxicity in Breast Cancer: A Missed Opportunity in Cardio-Oncology Risk Stratification?

ByChinemerem M. Emeasoba,Chiugo Okoye,Uchenna M. Amaechi,Hanna Jensen

June 12th 2026

Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care.

73 The ADC Era in Breast Cancer: Contemporary Sequencing Strategies and Evidence-Based Toxicity Management

ByChiugo Okoye,Chinemerem M. Emeasoba,Olanipekun Ntukidem,Uchechi Amaechi,Chidi Obialo-Ibeawuchi

June 11th 2026

Explore how ADCs reshape breast cancer care, with practical sequencing strategies across subtypes and guideline-based toxicity management for ILD, neutropenia, and GI effects.

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

144 A Comparative Analysis of Pregnancy-Related Breast Cancer Outcomes Versus Non-Pregnant Breast Cancer Patients—A TriNetX Real-World Analysis

ByUchenna M. Amaechi,Samrawit Zinabu,Chiugo Okoye,Oladayo Oyebanji,Chinemerem M. Emeasoba,Miriam Michael

April 29th 2026

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

ByUchenna M. Amaechi,Kenneth Ssebambulidde,Chiugo Okoye,Oladayo Oyebanji,Chinemerem M. Emeasoba,Miriam Michael

April 28th 2026

Latest Updated Articles

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis
April 28th 2026

Chinemerem M. Emeasoba

Articles by Chinemerem M. Emeasoba

72 Clonal Hematopoiesis and Anthracycline Cardiotoxicity in Breast Cancer: A Missed Opportunity in Cardio-Oncology Risk Stratification?

73 The ADC Era in Breast Cancer: Contemporary Sequencing Strategies and Evidence-Based Toxicity Management

144 A Comparative Analysis of Pregnancy-Related Breast Cancer Outcomes Versus Non-Pregnant Breast Cancer Patients—A TriNetX Real-World Analysis

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

Latest Updated Articles

Trending on CancerNetwork

Capivasertib Combo Earns FDA Approval in PTEN-Deficient Metastatic HSPC

FDA Approves Adjuvant Belzutifan/Pembrolizumab in Clear Cell RCC Post Nephrectomy

Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer

Tisa-Cel Yields Enduring Remissions in Younger High-Risk B-ALL Population

Azacitidine Triplet Produces Durable MRD-Negative Remissions in IDH1+ AML